Tata Capital IPO Listing LIVE: Shares to Debut on October 13; GMP and Expert Insights
Tata Capital IPO is scheduled to list on October 13, 2025. The IPO was oversubscribed 1.95 times, with muted GMP of ₹0, suggesting a listing near the issue price of ₹326.
Tata Capital IPO is scheduled to list on October 13, 2025. The IPO was oversubscribed 1.95 times, with muted GMP of ₹0, suggesting a listing near the issue price of ₹326.
The Tata Capital IPO was scheduled to be listed on the stock market on Monday, October 13, 2025. The allotment was completed on October 9, and all eyes are now set on the listing price and potential listing gains.
IPO Subscription Status
The Tata Capital IPO was oversubscribed 1.95 times, with applications received for 65.12 crore shares against 33.34 crore shares on offer. Breaking down by investor category:
Qualified Institutional Buyers (QIBs): 3.42x subscription, applying for 32.45 crore shares against 9.49 crore on offer.
Non-Institutional Investors (NIIs): 1.98x subscription, applying for 14.11 crore shares versus 7.12 crore available.
Retail Individual Investors (RIIs): 1.10x subscription, with 18.22 crore shares applied against 16.61 crore allocated.
Grey Market Premium (GMP) and Listing Price
Tata Capital shares are commanding a muted GMP of ₹0, indicating that the expected listing price is likely to be the same as the IPO price of ₹326.
Experts suggest that while the IPO saw healthy investor interest, the limited grey market activity signals a neutral debut, with minimal listing gains expected.
Listing Details
The IPO shares will list on both BSE and NSE on October 13, 2025. Investors can track the allotment status online via the BSE investor portal.
Market Context
The listing season coincides with the September quarter earnings season, which will commence next week with marquee companies such as Reliance Industries, Infosys, HDFC Bank, Wipro, Tech Mahindra, IRFC, Nestle India, HCL Tech, and IREDA announcing their results.
Vinod Nair, Head of Research at Geojit Investments, said:
“The domestic market showed gains amid Q2 results, while metals indices outperformed. Although expectations are modest for sectors like finance, IT, and pharma, the market is likely to rebound strongly in H2FY26 with a recovery in domestic demand.”
